Blockade of autoreceptor-mediated inhibition of norepinephrine release by atipamezole is maintained after chronic reuptake inhibition

International Journal of Neuropsychopharmacology

Volumn 10, Issue 6, 2007, Pages 827-833

  Lapiz, M Danet ^a   Zhao, Zaorui ^b   Bondi, Corina O ^a   O'Donnell, James M ^b   Morilak, David A ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Antidepressant; Atipamezole; Autoreceptor; Desipramine; Norepinephrine

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; ATIPAMEZOLE; AUTORECEPTOR; DESIPRAMINE;

ANIMAL EXPERIMENT; ARTICLE; DESENSITIZATION; DRUG MECHANISM; MALE; MICRODIALYSIS; NEUROTRANSMISSION; NONHUMAN; NORADRENALIN RELEASE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC UPTAKE INHIBITORS; ANIMALS; AUTORECEPTORS; DESIPRAMINE; DOPAMINE; IMIDAZOLES; MALE; NOREPINEPHRINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-2;

EID: 35648960771     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145707007651     Document Type: Article

References (17)

1. Artigas F, Celada P, Laruelle M, Adell A (2001). How does pindolol improve antidepressant action? Trends in Pharmacological Science 22, 224-228.
2. Béïque J-C, de Montigny C, Blier P, Debonnel G (2000). Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: I. In vivo electrophysiological studies in the rat. Neuropharmacology 39, 1800-1812.
3. Benmansour S, Altamirano AV, Jones DJ, Sanchez TA, Gould GG, Pardon M-C, Morilak DA, Frazer A (2004). Regulation of the norepinephrine transporter by chronic administration of antidepressants. Biological Psychiatry 55, 313-316.
4. Benmansour S, Owen WA, Cecchi M, Morilak DA, Frazer A (2002). Serotonin clearance in vivo is altered to a greater extent by antidepressant-induced downregulation of the serotonin transporter than by acute blockade of this transporter. Journal of Neuroscience 22, 6766-6772.
5. Blier P, de Montigny C (1994). Current advances and trends in the treatment of depression. Trends in Pharmacological Science 15, 220-226.
6. Blier P, de Montigny C (1999). Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Neuropsychopharmacology 21, 91S-98S.
7. Garcia AS, Barrera G, Burke TF, Ma S, Hensler JG, Morilak DA (2004). Autoreceptor-mediated inhibition of norepinephrine release in rat medial prefrontal cortex is maintained after chronic desipramine treatment. Journal of Neurochemistry 91, 683-693.
8. 2-adrenoceptor antagonist, atipamezole. European Journal of Pharmacology 347, 29-40.
9. 2-adrenoceptor blockade. Biological Psychiatry 46, 766-774.
10. 2A adrenoceptors. Naunyn-Schmiedeberg's Archives of Pharmacology 358, 197-206.
11. Paxinos G, Watson C (1998). The Rat Brain in Stereotaxic Coordinates (4th edn). San Diego: Academic Press.
12. Piñeyro G, Blier P (1999). Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacological Reviews 51, 533-591.
13. 2-adrenoceptors. Naunyn-Schmiedeberg's Archives of Pharmacology 363, 66-72.
14. Svensson TH (1980). Effect of chronic treatment with tricyclic antidepressant drugs on identified brain noradrenergic and serotonergic neurons. Acta Psychiatrica Scandinavica 61 (Suppl. 280), 121-131.
15. Szabo ST, Blier P (2001). Effect of the selective noradrenergic reuptake inhibitor reboxetine on the firing activity of noradrenaline and serotonin neurons. European Journal of Neuroscience 13, 2077-2087.
16. Szabo ST, de Montigny C, Blier P (2000). Progressive attenuation of the firing activity of locus coeruleus noradrenergic neurons by sustained administration of selective serotonin reuptake inhibitors. International Journal of Neuropsychopharmacology 3, 1-11.
17. Versiani M, Cassano G, Perugi G, Benedetti A, Mastalli L, Nardi A, Savino M (2002). Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. Journal of Clinical Psychiatry 63, 31-37.